MediciNova completes last patient visit in double-blind portion of Phase 2B/3 COMBAT-ALS trial
MNOV•MediciNova announced completion of the last patient visit in the double-blind portion of its Phase 2B/3 COMBAT-ALS trial of MN-166 (ibudilast). Topline results are expected by the end of 2026.
1. Trial milestone
MediciNova said the last patient visit in the double-blind portion of its Phase 2B/3 COMBAT-ALS trial of MN-166 (ibudilast) is complete. The company expects topline results from that portion by the end of 2026.
